Chuikyo Rep Calls for Modifying Re-Pricing Criteria with Eye to Xolair’s Pollen Allergy Use

Chuikyo General Meeting on November 13 A payer member of a key reimbursement policy panel on November 13 urged the health ministry to revise the current criteria for “indication change re-pricing” to address sales growth anticipated for Novartis’ asthma drug...read more